VEGFA and age-related macular degeneration: The major accomplishments at NeXstar centered on Macugen, the first VEGF antagonist approved for use in age-related macular degeneration (AMD), and also on the PDGF aptamer antagonist that is today undergoing clinical development by Ophthotech (this compound is also for AMD, and appears—as Nebojsa Janjic predicted almost 20 years ago—that inhibiting PDGF and VEGF would synergize for diseases characterized by abundant and inappropriate angiogenesis, including that process in the “wet” form of AMD).